US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

Morningstar analysis suggests U.S. President Trump's proposed pharmaceutical import duties and drug price reduction initiatives will have a manageable impact on major U.S. and European drugmakers. The report estimates that an initial 15% U.S. tariff on pharmaceuticals would peak at approximately 4% of core profit on average for analyzed companies, after mitigation efforts. Furthermore, the near-term risk from matching overseas drug prices is deemed "exceedingly low," indicating that while some financial adjustments are expected, the industry is positioned to absorb these changes without significant long-term disruption, partly due to ongoing investments in U.S. manufacturing capacity.

Analysis

A Morningstar analysis suggests that the financial impact of proposed U.S. pharmaceutical import duties and drug price reduction measures is likely to be manageable for ten major U.S. and European drugmakers, including Pfizer, Merck, Novartis, and AstraZeneca. The direct risk from the push to align U.S. drug prices with lower overseas benchmarks is assessed as "exceedingly low" for the near term, primarily due to the potential for such policies to disrupt patient access to medications. Quantitatively, an initial 15% U.S. tariff on pharmaceuticals is estimated to reduce core profits by a peak of approximately 4% on average after mitigation efforts are factored in. While companies are proactively scaling up U.S. manufacturing to preemptively address these trade policies, this strategic shift carries long-term financial implications. All firms analysed will likely face higher future tax burdens from relocating production, and European drugmakers, in particular, will incur elevated costs associated with establishing new U.S. facilities. The stated threat of tariffs escalating to 250% remains a significant, though unquantified, tail risk to this otherwise contained outlook.

Key Decisions for Investors

• Given the assessment that the initial tariff impact is manageable at a ~4% hit to core profit, the recent regulatory overhang on these pharmaceutical stocks may be partially de-risked, supporting a decision to maintain or add to core positions.
• Investors should monitor company-specific capital allocation, particularly for European firms like Novartis and Sanofi, which face higher costs to build out U.S. manufacturing compared to their American counterparts.
• It is crucial to track any policy rhetoric or legislative action that suggests tariffs could escalate towards the threatened 250% level, as this would fundamentally alter the current risk profile and necessitate a re-evaluation of sector exposure.
• Focus on the effectiveness of announced mitigation strategies, as companies that can more efficiently shift their supply chains and manufacturing to the U.S. will likely outperform peers in this new regulatory environment.